Log In
Print
BCIQ
Print
Print this Print this
 

Mavrilimumab (CAM-3001)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHuman monoclonal antibody (mAb) targeting the alpha subunit of the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today